You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

For patient information about regimens that include both chemotherapy and immunotherapy, download Treating cancer with chemotherapy and immunotherapy: What you need to know.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Regimens

28 Items
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Jun 2017
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Leukemia - Acute Myeloid (AML)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023
Cancer Type:
Sarcoma, 
Ewing's, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
Jul 2019
Cancer Type:
Sarcoma, 
Ewing's
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Sep 2019
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    vanDETanib - Monotherapy for symptomatic and/or progressive medullary thyroid cancer (MTC), with specific criteria
Nov 2023
Intent: Palliative
Funding:
Exceptional Access Program
    vemURAFenib - Monotherapy in patients with BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma, with specific criteria
Aug 2023
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Intent: Palliative
Aug 2023
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Intent: Palliative
Mar 2022

Pages